Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 127

1.

Complexity of PEComas : Diagnostic approach, molecular background, clinical management.

Utpatel K, Calvisi DF, Köhler G, Kühnel T, Niesel A, Verloh N, Vogelhuber M, Neu R, Hosten N, Schildhaus HU, Dietmaier W, Evert M.

Pathologe. 2019 Jul 15. doi: 10.1007/s00292-019-0612-5. [Epub ahead of print] Review.

PMID:
31309284
2.

KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors - TORC1/2 Inhibition as Salvage Strategy.

Mühlenberg T, Ketzer J, Heinrich MC, Grunewald S, Marino-Enriquez A, Trautmann M, Hartmann W, Wardelmann E, Treckmann J, Worm K, Bertram S, Herold T, Schildhaus HU, Glimm H, Stenzinger A, Brors B, Horak P, Hohenberger P, Fröhling S, Fletcher JA, Bauer S.

Mol Cancer Ther. 2019 Nov;18(11):1985-1996. doi: 10.1158/1535-7163.MCT-18-1224. Epub 2019 Jul 15.

PMID:
31308077
3.

[Erratum to: Complexity of PEComas : Diagnostic approach, molecular background, clinical management].

Utpatel K, Calvisi DF, Köhler G, Kühnel T, Niesel A, Verloh N, Vogelhuber M, Neu R, Hosten N, Schildhaus HU, Dietmaier W, Evert M.

Pathologe. 2019 Jul;40(4):454. doi: 10.1007/s00292-019-0636-x. German. No abstract available.

PMID:
31263908
4.

[Epithelioid, biphasic and mixed tumors of soft tissue].

Evert M, Schildhaus HU.

Pathologe. 2019 Jul;40(4):393-411. doi: 10.1007/s00292-019-0627-y. German.

PMID:
31243551
5.

[Systemic therapy of sarcomas : New biomarkers and therapeutic strategies].

Bauer S, Dirksen U, Schildhaus HU.

Pathologe. 2019 Jul;40(4):436-442. doi: 10.1007/s00292-019-0628-x. German.

PMID:
31243550
6.

[Round-cell sarcomas].

Schildhaus HU, Evert M.

Pathologe. 2019 Jul;40(4):366-380. doi: 10.1007/s00292-019-0633-0. Review. German.

PMID:
31240453
7.

[Complexity of PEComas : Diagnostic approach, molecular background, clinical management (German version)].

Utpatel K, Calvisi DF, Köhler G, Kühnel T, Niesel A, Verloh N, Vogelhuber M, Neu R, Hosten N, Schildhaus HU, Dietmaier W, Evert M.

Pathologe. 2019 Jul;40(4):443-453. doi: 10.1007/s00292-019-0614-3. German. Erratum in: Pathologe. 2019 Jul 1;:.

PMID:
31165234
8.

[Erratum to: Predictive value of PD-L1 diagnostics].

Schildhaus HU.

Pathologe. 2019 May;40(3):275. doi: 10.1007/s00292-019-0582-7. German. No abstract available.

PMID:
31144079
9.

Monitoring efficacy of checkpoint inhibitor therapy in patients with non-small-cell lung cancer.

Schiwitza A, Schildhaus HU, Zwerger B, Rüschoff J, Reinhardt C, Leha A, Andreas S, Rittmeyer A.

Immunotherapy. 2019 Jun;11(9):769-782. doi: 10.2217/imt-2019-0039.

10.

Automated density-based counting of FISH amplification signals for HER2 status assessment.

Höfener H, Homeyer A, Förster M, Drieschner N, Schildhaus HU, Hahn HK.

Comput Methods Programs Biomed. 2019 May;173:77-85. doi: 10.1016/j.cmpb.2019.03.006. Epub 2019 Mar 14.

11.

Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.

Michels S, Massutí B, Schildhaus HU, Franklin J, Sebastian M, Felip E, Grohé C, Rodriguez-Abreu D, Abdulla DSY, Bischoff H, Brandts C, Carcereny E, Corral J, Dingemans AC, Pereira E, Fassunke J, Fischer RN, Gardizi M, Heukamp L, Insa A, Kron A, Menon R, Persigehl T, Reck M, Riedel R, Rothschild SI, Scheel AH, Scheffler M, Schmalz P, Smit EF, Limburg M, Provencio M, Karachaliou N, Merkelbach-Bruse S, Hellmich M, Nogova L, Büttner R, Rosell R, Wolf J.

J Thorac Oncol. 2019 Jul;14(7):1266-1276. doi: 10.1016/j.jtho.2019.03.020. Epub 2019 Apr 9.

PMID:
30978502
12.

Canonical WNT/β-Catenin Signaling Plays a Subordinate Role in Rhabdomyosarcomas.

Ragab N, Viehweger F, Bauer J, Geyer N, Yang M, Seils A, Belharazem D, Brembeck FH, Schildhaus HU, Marx A, Hahn H, Simon-Keller K.

Front Pediatr. 2018 Dec 5;6:378. doi: 10.3389/fped.2018.00378. eCollection 2018.

13.

[Predictive value of PD-L1 diagnostics].

Schildhaus HU.

Pathologe. 2018 Nov;39(6):498-519. doi: 10.1007/s00292-018-0507-x. Review. German. Erratum in: Pathologe. 2019 May;40(3):275.

PMID:
30367225
14.

PI3K: A master regulator of brain metastasis-promoting macrophages/microglia.

Blazquez R, Wlochowitz D, Wolff A, Seitz S, Wachter A, Perera-Bel J, Bleckmann A, Beißbarth T, Salinas G, Riemenschneider MJ, Proescholdt M, Evert M, Utpatel K, Siam L, Schatlo B, Balkenhol M, Stadelmann C, Schildhaus HU, Korf U, Reinz E, Wiemann S, Vollmer E, Schulz M, Ritter U, Hanisch UK, Pukrop T.

Glia. 2018 Nov;66(11):2438-2455. doi: 10.1002/glia.23485. Epub 2018 Oct 25.

PMID:
30357946
15.

Loss of RNF40 Decreases NF-κB Activity in Colorectal Cancer Cells and Reduces Colitis Burden in Mice.

Kosinsky RL, Chua RL, Qui M, Saul D, Mehlich D, Ströbel P, Schildhaus HU, Wegwitz F, Faubion WA, Johnsen SA.

J Crohns Colitis. 2019 Mar 26;13(3):362-373. doi: 10.1093/ecco-jcc/jjy165.

PMID:
30321325
16.

Different Response of Ptch Mutant and Ptch Wildtype Rhabdomyosarcoma Toward SMO and PI3K Inhibitors.

Geyer N, Ridzewski R, Bauer J, Kuzyakova M, Dittmann K, Dullin C, Rosenberger A, Schildhaus HU, Uhmann A, Fulda S, Hahn H.

Front Oncol. 2018 Sep 25;8:396. doi: 10.3389/fonc.2018.00396. eCollection 2018.

17.

CIC fusion-positive sarcoma of the spermatic cord.

Bremmer F, Fichtner A, Triefenbach R, Inniger R, Mayer P, Lukat L, Ströbel P, Schildhaus HU.

Virchows Arch. 2019 Feb;474(2):253-257. doi: 10.1007/s00428-018-2471-5. Epub 2018 Oct 11.

PMID:
30310990
18.

[FGFR3 overexpression is a relevant alteration in colorectal cancer].

Fromme JE, Schildhaus HU.

Pathologe. 2018 Dec;39(Suppl 2):189-192. doi: 10.1007/s00292-018-0504-0. Review. German.

PMID:
30267148
19.

FGFR3 mRNA overexpression defines a subset of oligometastatic colorectal cancers with worse prognosis.

Fromme JE, Schmitz K, Wachter A, Grzelinski M, Zielinski D, Koppel C, Conradi LC, Homayounfar K, Hugo T, Hugo S, Lukat L, Rüschoff J, Ströbel P, Ghadimi M, Beißbarth T, Reuter-Jessen K, Bleckmann A, Schildhaus HU.

Oncotarget. 2018 Aug 14;9(63):32204-32218. doi: 10.18632/oncotarget.25941. eCollection 2018 Aug 14.

20.

Using RNA-Seq Data for the Detection of a Panel of Clinically Relevant Mutations.

Wolff A, Perera-Bel J, Schildhaus HU, Homayounfar K, Schatlo B, Bleckmann A, Beißbarth T.

Stud Health Technol Inform. 2018;253:217-221.

PMID:
30147077
21.

Comparative proteomics reveals a diagnostic signature for pulmonary head-and-neck cancer metastasis.

Bohnenberger H, Kaderali L, Ströbel P, Yepes D, Plessmann U, Dharia NV, Yao S, Heydt C, Merkelbach-Bruse S, Emmert A, Hoffmann J, Bodemeyer J, Reuter-Jessen K, Lois AM, Dröge LH, Baumeister P, Walz C, Biggemann L, Walter R, Häupl B, Comoglio F, Pan KT, Scheich S, Lenz C, Küffer S, Bremmer F, Kitz J, Sitte M, Beißbarth T, Hinterthaner M, Sebastian M, Lotz J, Schildhaus HU, Wolff H, Danner BC, Brandts C, Büttner R, Canis M, Stegmaier K, Serve H, Urlaub H, Oellerich T.

EMBO Mol Med. 2018 Sep;10(9). pii: e8428. doi: 10.15252/emmm.201708428.

22.

Optimization and validation of PD-L1 immunohistochemistry staining protocols using the antibody clone 28-8 on different staining platforms.

Koppel C, Schwellenbach H, Zielinski D, Eckstein S, Martin-Ortega M, D'Arrigo C, Schildhaus HU, Rüschoff J, Jasani B.

Mod Pathol. 2018 Nov;31(11):1630-1644. doi: 10.1038/s41379-018-0071-1. Epub 2018 Jun 26.

23.

Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment.

Ihle MA, Huss S, Jeske W, Hartmann W, Merkelbach-Bruse S, Schildhaus HU, Büttner R, Sihto H, Sundby Hall K, Eriksson M, Reichardt P, Joensuu H, Wardelmann E.

PLoS One. 2018 Feb 16;13(2):e0193048. doi: 10.1371/journal.pone.0193048. eCollection 2018.

24.

EGFR immunohistochemistry as biomarker for antibody-based therapy of squamous NSCLC - Experience from the first ring trial of the German Quality Assurance Initiative for Pathology (QuIP®).

Petersen I, Dietel M, Geilenkeuser WJ, Mireskandari M, Weichert W, Steiger K, Scheel AH, Büttner R, Schirmacher P, Warth A, Lasitschka F, Schildhaus HU, Kirchner T, Reu S, Kreipe H, Länger F, Tiemann M, Schulte C, Jöhrens K.

Pathol Res Pract. 2017 Dec;213(12):1530-1535. doi: 10.1016/j.prp.2017.09.021. Epub 2017 Sep 28.

25.

MET-GRB2 Signaling-Associated Complexes Correlate with Oncogenic MET Signaling and Sensitivity to MET Kinase Inhibitors.

Smith MA, Licata T, Lakhani A, Garcia MV, Schildhaus HU, Vuaroqueaux V, Halmos B, Borczuk AC, Chen YA, Creelan BC, Boyle TA, Haura EB.

Clin Cancer Res. 2017 Nov 15;23(22):7084-7096. doi: 10.1158/1078-0432.CCR-16-3006. Epub 2017 Aug 29.

26.

Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer.

Scheel AH, Baenfer G, Baretton G, Dietel M, Diezko R, Henkel T, Heukamp LC, Jasani B, Jöhrens K, Kirchner T, Lasitschka F, Petersen I, Reu S, Schildhaus HU, Schirmacher P, Schwamborn K, Sommer U, Stoss O, Tiemann M, Warth A, Weichert W, Wolf J, Büttner R, Rüschoff J.

Histopathology. 2018 Feb;72(3):449-459. doi: 10.1111/his.13375. Epub 2017 Nov 21.

PMID:
28851100
27.

Current Standard and Future Perspectives in the Treatment of Gastrointestinal Stromal Tumors.

Cameron S, Beham A, Schildhaus HU.

Digestion. 2017;95(4):262-268. doi: 10.1159/000455835. Epub 2017 Apr 7.

28.

Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4- and MYC-dependent manner.

Mishra VK, Wegwitz F, Kosinsky RL, Sen M, Baumgartner R, Wulff T, Siveke JT, Schildhaus HU, Najafova Z, Kari V, Kohlhof H, Hessmann E, Johnsen SA.

Nucleic Acids Res. 2017 Jun 20;45(11):6334-6349. doi: 10.1093/nar/gkx212.

29.

Diagnostic red flags: steroid-treated malignant CNS lymphoma mimicking autoimmune inflammatory demyelination.

Barrantes-Freer A, Engel AS, Rodríguez-Villagra OA, Winkler A, Bergmann M, Mawrin C, Kuempfel T, Pellkofer H, Metz I, Bleckmann A, Hernández-Durán S, Schippling S, Rushing EJ, Frank S, Glatzel M, Matschke J, Hartmann C, Reifenberger G, Müller W, Schildhaus HU, Brück W, Stadelmann C.

Brain Pathol. 2018 Mar;28(2):225-233. doi: 10.1111/bpa.12496. Epub 2017 Apr 6.

PMID:
28213912
30.

The role of beta-catenin mutation and SOX9 expression in sex cord-stromal tumours of the testis.

Bremmer F, Behnes CL, Schildhaus HU, Gaisa NT, Reis H, Jarry H, Radzun HJ, Stroebel P, Schweyer S.

Virchows Arch. 2017 Apr;470(4):421-428. doi: 10.1007/s00428-017-2090-6. Epub 2017 Feb 16.

PMID:
28204871
31.

Context-Dependent Epigenetic Regulation of Nuclear Factor of Activated T Cells 1 in Pancreatic Plasticity.

Chen NM, Neesse A, Dyck ML, Steuber B, Koenig AO, Lubeseder-Martellato C, Winter T, Forster T, Bohnenberger H, Kitz J, Reuter-Jessen K, Griesmann H, Gaedcke J, Grade M, Zhang JS, Tsai WC, Siveke J, Schildhaus HU, Ströbel P, Johnsen SA, Ellenrieder V, Hessmann E.

Gastroenterology. 2017 May;152(6):1507-1520.e15. doi: 10.1053/j.gastro.2017.01.043. Epub 2017 Feb 8.

32.

Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rare events.

Huss S, Pasternack H, Ihle MA, Merkelbach-Bruse S, Heitkötter B, Hartmann W, Trautmann M, Gevensleben H, Büttner R, Schildhaus HU, Wardelmann E.

Hum Pathol. 2017 Apr;62:206-214. doi: 10.1016/j.humpath.2017.01.005. Epub 2017 Feb 1. Review.

PMID:
28159677
33.

[Predictive PD-L1 immunohistochemistry for non-small cell lung cancer : Current state of the art and experiences of the first German harmonization study].

Scheel AH, Dietel M, Heukamp LC, Jöhrens K, Kirchner T, Reu S, Rüschoff J, Schildhaus HU, Schirmacher P, Tiemann M, Warth A, Weichert W, Fischer RN, Wolf J, Büttner R.

Pathologe. 2016 Nov;37(6):557-567. Review. German.

PMID:
27510417
34.

HR23b expression is a potential predictive biomarker for HDAC inhibitor treatment in mesenchymal tumours and is associated with response to vorinostat.

Angelika Ihle M, Merkelbach-Bruse S, Hartmann W, Bauer S, Ratner N, Sonobe H, Nishio J, Larsson O, Åman P, Pedeutour F, Taguchi T, Wardelmann E, Buettner R, Schildhaus HU.

J Pathol Clin Res. 2016 Feb 5;2(2):59-71. doi: 10.1002/cjp2.35. eCollection 2016 Apr.

35.

Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas.

Scheel AH, Dietel M, Heukamp LC, Jöhrens K, Kirchner T, Reu S, Rüschoff J, Schildhaus HU, Schirmacher P, Tiemann M, Warth A, Weichert W, Fischer RN, Wolf J, Buettner R.

Mod Pathol. 2016 Oct;29(10):1165-72. doi: 10.1038/modpathol.2016.117. Epub 2016 Jul 8.

36.

Spindle cell embryonal rhabdomyosarcoma of the prostate in an adult patient - case report and review of clinicopathological features.

Schildhaus HU, Lokka S, Fenner W, Küster J, Kühnle I, Heinmöller E.

Diagn Pathol. 2016 Jun 29;11(1):56. doi: 10.1186/s13000-016-0507-1. Review.

37.

[Sarcoma of the spleen with MDM2 expression].

Hansen T, Titze U, Deeb A, Eikötter B, Schütz M, Schildhaus HU.

Pathologe. 2016 Jul;37(4):367-70. doi: 10.1007/s00292-016-0168-6. German.

PMID:
27271257
38.

Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors.

Ortiz-Cuaran S, Scheffler M, Plenker D, Dahmen L, Scheel AH, Fernandez-Cuesta L, Meder L, Lovly CM, Persigehl T, Merkelbach-Bruse S, Bos M, Michels S, Fischer R, Albus K, König K, Schildhaus HU, Fassunke J, Ihle MA, Pasternack H, Heydt C, Becker C, Altmüller J, Ji H, Müller C, Florin A, Heuckmann JM, Nuernberg P, Ansén S, Heukamp LC, Berg J, Pao W, Peifer M, Buettner R, Wolf J, Thomas RK, Sos ML.

Clin Cancer Res. 2016 Oct 1;22(19):4837-4847. Epub 2016 Jun 1.

39.

How to Treat INI1 Negative Non-Rhabdoid Tumours in Adolescents: Following Genotype or Histological Phenotype?

Völker F, Kühnle I, Edler J, Schildhaus HU, Vokuhl C, Mohr A, Sahlmann C, Kramm CM.

Klin Padiatr. 2016 Nov;228(6-07):341-343. Epub 2016 May 31. No abstract available.

PMID:
27246730
40.

Partial Response to First-Line Crizotinib in an Elderly Male Patient with ROS1 Translocation-Positive Lung Cancer.

Overbeck TR, Schmitz K, Engelke C, Sahlmann CO, Hugo S, Kellner L, Trümper L, Schildhaus HU.

Case Rep Oncol. 2016 Mar 10;9(1):158-63. doi: 10.1159/000444745. eCollection 2016 Jan-Apr.

41.

Heterogeneity of KRAS Mutation Status in Rectal Cancer.

Jo P, König A, Schirmer M, Kitz J, Conradi LC, Azizian A, Bernhardt M, Wolff HA, Grade M, Ghadimi M, Ströbel P, Schildhaus HU, Gaedcke J.

PLoS One. 2016 Apr 11;11(4):e0153278. doi: 10.1371/journal.pone.0153278. eCollection 2016.

42.

Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients.

Michels S, Scheel AH, Scheffler M, Schultheis AM, Gautschi O, Aebersold F, Diebold J, Pall G, Rothschild S, Bubendorf L, Hartmann W, Heukamp L, Schildhaus HU, Fassunke J, Ihle MA, Künstlinger H, Heydt C, Fischer R, Nogovà L, Mattonet C, Hein R, Adams A, Gerigk U, Schulte W, Lüders H, Grohé C, Graeven U, Müller-Naendrup C, Draube A, Kambartel KO, Krüger S, Schulze-Olden S, Serke M, Engel-Riedel W, Kaminsky B, Randerath W, Merkelbach-Bruse S, Büttner R, Wolf J.

J Thorac Oncol. 2016 Jan;11(1):122-7. doi: 10.1016/j.jtho.2015.09.016.

43.

Impact of updated HER2 testing guidelines in breast cancer--re-evaluation of HERA trial fluorescence in situ hybridization data.

Stoss OC, Scheel A, Nagelmeier I, Schildhaus HU, Henkel T, Viale G, Jasani B, Untch M, Rüschoff J.

Mod Pathol. 2015 Dec;28(12):1528-34. doi: 10.1038/modpathol.2015.112. Epub 2015 Sep 25.

44.

Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68Ga-PSMA-positron emission tomography/computerized tomography.

Hijazi S, Meller B, Leitsmann C, Strauss A, Meller J, Ritter CO, Lotz J, Schildhaus HU, Trojan L, Sahlmann CO.

Prostate. 2015 Dec;75(16):1934-40. doi: 10.1002/pros.23091. Epub 2015 Sep 10.

PMID:
26356236
45.

Ovarian-type epithelial tumours of the testis: immunohistochemical and molecular analysis of two serous borderline tumours of the testis.

Bürger T, Schildhaus HU, Inniger R, Hansen J, Mayer P, Schweyer S, Radzun HJ, Ströbel P, Bremmer F.

Diagn Pathol. 2015 Jul 22;10:118. doi: 10.1186/s13000-015-0342-9.

46.

SRC inhibition represents a potential therapeutic strategy in liposarcoma.

Sievers E, Trautmann M, Kindler D, Huss S, Gruenewald I, Dirksen U, Renner M, Mechtersheimer G, Pedeutour F, Åman P, Nishio J, Schildhaus HU, Kirfel J, Schirmacher P, Wardelmann E, Buettner R, Hartmann W.

Int J Cancer. 2015 Dec 1;137(11):2578-88. doi: 10.1002/ijc.29645. Epub 2015 Jul 6.

47.

FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro.

Künstlinger H, Fassunke J, Schildhaus HU, Brors B, Heydt C, Ihle MA, Mechtersheimer G, Wardelmann E, Büttner R, Merkelbach-Bruse S.

Oncotarget. 2015 Aug 21;6(24):20215-30.

48.

Fibroblast Growth Factor Receptor 1 and Related Ligands in Small-Cell Lung Cancer.

Zhang L, Yu H, Badzio A, Boyle TA, Schildhaus HU, Lu X, Dziadziuszko R, Jassem J, Varella-Garcia M, Heasley LE, Kowalewski AA, Ellison K, Chen G, Zhou C, Hirsch FR.

J Thorac Oncol. 2015 Jul;10(7):1083-90. doi: 10.1097/JTO.0000000000000562.

49.

Clear cell papillary renal cell carcinoma and renal angiomyoadenomatous tumor: two variants of a morphologic, immunohistochemical, and genetic distinct entity of renal cell carcinoma.

Deml KF, Schildhaus HU, Compérat E, von Teichman A, Storz M, Schraml P, Bonventre JV, Fend F, Fleige B, Nerlich A, Gabbert HE, GaBler N, Grobholz R, Hailemariam S, Hinze R, Knüchel R, Lhermitte B, Nesi G, Rüdiger T, Sauter G, Moch H.

Am J Surg Pathol. 2015 Jul;39(7):889-901. doi: 10.1097/PAS.0000000000000456.

50.

miRNA-221 and miRNA-222 induce apoptosis via the KIT/AKT signalling pathway in gastrointestinal stromal tumours.

Ihle MA, Trautmann M, Kuenstlinger H, Huss S, Heydt C, Fassunke J, Wardelmann E, Bauer S, Schildhaus HU, Buettner R, Merkelbach-Bruse S.

Mol Oncol. 2015 Aug;9(7):1421-33. doi: 10.1016/j.molonc.2015.03.013. Epub 2015 Apr 10.

Supplemental Content

Loading ...
Support Center